Duvelisib Capsule
NDC Package 11014-0348-2

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Duvelisib capsules is a medication used to treat certain types of cancer (such as chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma). This formulation utilizes a capsule delivery system. Marketed by Catalent Pharma Solutions, Llc, this product is identified by NDC 11014-0348.

Identification & Billing

NDC Package Code
11014-0348-2
Package Description
1 BAG in 1 DRUM / 100000 CAPSULE in 1 BAG
Product Code
11014-0348
11-Digit Billing Format
11014034802

Clinical Specifications

Proprietary Name
Duvelisib
Non-Proprietary Name
Duvelisib
Substance Name
Duvelisib
Dosage Form
Capsule - A solid oral dosage form consisting of a shell and a filling. The shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band. Capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed.
Active Ingredient(s)
DUVELISIB 25 mg/1
Usage Information
This medication is used to treat certain types of cancer (such as chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma). Duvelisib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Regulatory & Marketing

Labeler Name
Catalent Pharma Solutions, Llc
Product Type
Drug For Further Processing
Marketing Category
DRUG FOR FURTHER PROCESSING - A drug (other than the bulk ingredient API) that is in an interim stage of manufacture, processing, preparation, or packaging, and not ready for human or animal use.
Start Marketing Date
09-25-2018
Listing Expiration
12-31-2026
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 11014-0348-2 identifies a specific commercial package of 1 bag in 1 drum / 100000 capsule in 1 bag of Duvelisib (UNFINISHED drug), drug for further processing labeled by Catalent Pharma Solutions, Llc. This capsule is formulated for use and contains duvelisib as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Catalent Pharma Solutions, Llc on September 25, 2018. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is used to treat certain types of cancer (such as chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma). Duvelisib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

How is this Catalent Pharma Solutions, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 11014034802. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
11014-0348-2
11-Digit CMS (5-4-2)
11014-0348-02

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.